• Zhencang Zhou, Pengqiang Wu, Fujue Wang, Huan Tao, Yingying Chen, Jie Gao, Dengke Chen, and Yongqian Jia.
• Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
• Medicine (Baltimore). 2022 Mar 4; 101 (9): e28938e28938.

RationaleMarginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) has an indolent natural course and disseminates slowly. However, there is currently no consensus regarding the optimal treatment strategy for relapsed/refractory MALT lymphomas. Lenalidomide-bendamustine may be an effective regimen for such cases.Patient ConcernsA 48-year-old Chinese male patient with MALT lymphoma and API2/MALT received 2 courses of standard-dose rituximab, cyclophosphamide, vincristine, prednisone regimen chemotherapy combined with Helicobacter pylori eradication therapy. However, this disease was not effectively managed.DiagnosisMALT lymphoma.InterventionsThe patient received lenalidomide-bendamustine (lenalidomide 25 mg on days 1-21 and bendamustine 90 mg/m2 on days 1-2) for 6 courses.OutcomesLenalidomide-bendamustine was a safe and effective chemotherapy. No serious adverse events occurred during the treatment period. Ultrasound gastroscopy revealed that the tumor gradually shrank and eventually disappeared to complete remission.LessonsThe lenalidomide-bendamustine scheme might be a potentially effective option for patients with refractory or relapsed MALT lymphoma.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…